Antibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF1267 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Serpin C1/Antithrombin-III Biotinylated Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human Serpin C1/Antithrombin-III in Western blots. In Western blots, approximately 10% cross-reactivity with recombinant mouse (rm) Serpin C1 is observed and less than 1% cross-reactivity with recombinant human (rh) Serpin A1, rhSerpin A3, rhSerpin A4, rhSerpin A5, rhSerpin F2, rmSerpin D1, and rhPEDF is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Biotin
- Antigen sequence
P01008
- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Lowering Low-Density Lipoprotein Particles in Plasma Using Dextran Sulphate Co-Precipitates Procoagulant Extracellular Vesicles.
Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
Wang JW, Zhang YN, Sze SK, van de Weg SM, Vernooij F, Schoneveld AH, Tan SH, Versteeg HH, Timmers L, Lam CSP, de Kleijn DPV
International journal of molecular sciences 2017 Dec 29;19(1)
International journal of molecular sciences 2017 Dec 29;19(1)
Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL
Cancer letters 2010 Apr 1;290(1):49-57
Cancer letters 2010 Apr 1;290(1):49-57
No comments: Submit comment
No validations: Submit validation data